Advisors Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Advisors Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$72.8K	Sell	947 -47	-5%	-$3.67K	﹤0.01%	1268
2025 Q4	$78.5K	Sell	994 -11	-1%	-$952	﹤0.01%	1263
2025 Q3	$92.1K	Buy	1,005 +100	+11%	+$8.15K	﹤0.01%	1222
2025 Q2	$59.1K	Buy	905 +480	+113%	+$31.3K	﹤0.01%	1270
2025 Q1	$28.5K	Buy	+425	New	+$25.4K	﹤0.01%	1332
2020 Q4	–	Sell	-210	Closed	-$6K	–	1511
2020 Q3	$6K	Sell	210 -306	-59%	-$9.11K	﹤0.01%	1498
2020 Q2	$17K	Sell	516 -14	-3%	-$502	﹤0.01%	1474
2020 Q1	$22K	Sell	530 -55	-9%	-$2.92K	﹤0.01%	1380
2019 Q4	$36K	Buy	585 +28	+5%	+$1.85K	﹤0.01%	1426
2019 Q3	$41K	Buy	557 +235	+73%	+$17.6K	﹤0.01%	1414
2019 Q2	$26K	Buy	+322	New	+$22.9K	﹤0.01%	1446

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Advisors Asset Management's ANIP Position: Q1 2026 in Review

Advisors Asset Management reduced its ANI Pharmaceuticals (ANIP) stake by 4.7% in Q1 2026, selling an estimated $3.67K and leaving 947 shares worth $72.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

Advisors Asset Management first reported a position in ANIP in Q2 2019 and has held it in 11 quarters since. The position peaked at $92.1K in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

Advisors Asset Management held 947 shares of ANI Pharmaceuticals worth $72.8K as of Q1 2026.
Advisors Asset Management sold 47 ANI Pharmaceuticals shares in Q1 2026, an estimated $3.67K.
ANI Pharmaceuticals made up ﹤0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1268 holding.
Advisors Asset Management first reported a position in ANI Pharmaceuticals in Q2 2019 and has held it in 11 quarters since.
Advisors Asset Management's ANI Pharmaceuticals position peaked at $92.1K in Q3 2025.
280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.